
Objectives To evaluate whether circulating concentrations of angiogenic and cerebral biomarkers are associated with cerebral edema and infarcts in women with eclampsia or preeclampsia with severe features. Study design This prospective observational study included 45 women with eclampsia and 20 women with preeclampsia between April 2018 to November 2019. Magnetic resonance imaging (MRI) was performed to assess cerebral edema and infarcts. Plasma samples were collected at inclusion and analyzed for concentrations of neurofilament light (NfL), tau, glial fibrillary acidic protein (GFAP), placental growth factor (PlGF), soluble fms-like tyrosine kinase 1 (sFlt-1), and soluble endoglin (sEng). Concentrations were compared between women with or without cerebral edema and infarcts.Main outcome measuresMRI findings of cerebral edema and infarcts. Results Among women with eclampsia, concentrations of angiogenic and cerebral biomarkers did not differ according to the presence of cerebral edema or infarcts on MRI. In women with preeclampsia and cerebral edema (n = 4), concentrations of sFlt-1, the sFlt-1/PlGF ratio, and sEng were higher than in women without edema (n = 16), with adjusted fold changes (95% CI) of 4.21 (2.42–7.33), 6.10 (1.42–26.20), and 1.68 (1.10–2.56), respectively. The single woman with preeclampsia and cerebral infarcts had markedly elevated concentrations of several cerebral and angiogenic biomarkers. Conclusions Concentrations of angiogenic and cerebral biomarkers were not associated with the presence of cerebral edema or infarcts in women with eclampsia. Among women with preeclampsia, higher concentrations of several angiogenic and cerebral biomarkers were observed in women with cerebral edema or infarcts, although these findings require validation in larger cohorts.
BACKGROUND Preeclampsia is a serious gestational hypertensive disorder that affects the constrictive mechanisms of the umbilical vessels. Due to limited pharmacotherapy for preeclampsia, natural products (e.g., terpenes) stand out as raw materials for new vasodilators. The objective of this study is to demonstrate the vasorelaxant effect of the sesquiterpenoid (E,E)-farnesol on human umbilical arteries (hUA-PE) and veins (hUV-PE) from preeclamptic pregnancies. STUDY DESIGN hUA-PE and hUV-PE rings were mounted in organ bath for isometric recordings (ex vivo). The binding mode of (E,E)-farnesol to vascular targets was determined by molecular docking (in silico). RESULTS (E,E)-farnesol (1 μmol/L-1.2 mmol/L) induced concentration-dependent vasodilation in the basal and stimulated tone of hUA-PE and hUV-PE. There was an arteriovenous difference in the potency to relax vessels pre-contracted with KCl (60 mmol/L) (EC50: hUA-PE = 295.50 ± 9.26 μmol/L vs. hUV-PE = 83.83 ± 12.22 μmol/L; p < 0.0001) or 5-HT (10 μmol/L) (EC50: hUA-PE = 451.00 ± 3.63 μmol/L vs. hUV-PE = 172.90 ± 7.43 μmol/L; p < 0.0001). Pre-incubation with (E,E)-farnesol (1.2 mmol/L;±30 min) reduced basal tone and prevented vasoconstriction (by KCl/5-HT) in a time-dependent manner. (E,E)-farnesol interacted with L-type VOCC (-5.1 kcal/mol) and 5-HT1B/1D/2A receptors (≤ - 6.0 kcal/mol). TEA (1 mmol/L; non-specific K+ channel blocker) modified the potency of (E,E)-farnesol to relax 5-HT-induced vasoconstriction in hUA-PE (EC50: 399.42 ± 6.44 μmol/L) and hUV-PE (EC50: 360.42 ± 9.54 μmol/L). CONCLUSIONS This is the first study to demonstrate the potent vasodilatory effect of (E,E)-farnesol in preeclamptic umbilical vessels. Our findings expand the evidence regarding the action of natural products on the fetoplacental vasculature and position (E,E)-farnesol as a promising terpene for restoring vascular homeostasis in preeclampsia.
Background: Pre-eclampsia (PE) continues to be a major risk to maternal and fetal health, complicating up to 5% of all pregnancies, with no proven pharmacological intervention to reduce its incidence at term. Screening for pre-eclampsia risk at 35-36 weeks' gestation has been associated with a 30% reduction in the incidence of the primary outcome of PE, in The PREVENT-PE Trial. Methods: We aimed to understand women's maternity and birth experiences in The PREVENT-PE Trial. Semistructured interviews were conducted with women (N = 80) from The PREVENT-PE Trial including those who were screened and had a timed birth (n = 37); those who were randomised to usual care (n = 31); and those who declined randomisation (n = 12). Data were subjected to a Template Analysis, based on findings from previous studies on maternity care experiences. Findings: We report on four key themes: Achieving Efficiencies with Research-embedded Clinical Care; Communicating Trial Information; Building Relationships with Care Providers; and Agency and Shared Decisionmaking. Maternity service delivery was deemed to be efficient as was the care they received during the trial. Volume of complex medical information caused concern; however, regular, consistent contact between women and their healthcare providers, helped women feel valued and understood; especially when they were provided with the opportunity to ask questions and have them answered. Conclusion: Participation in an intervention trial within maternity care should embed principles of effective communication, relational care, shared decision-making, and efficient service delivery. Addressing these with not only enhance maternal experience but may also further promote greater participation in research.